M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
FDA approves AstraZeneca's SEROQUEL XR as add-on treatment of MDD
4 December 2009 - UK-based pharmaceutical company AstraZeneca Plc (LON: AZN) said today that the US Food and Drug Administration (FDA) approved its once-daily SEROQUEL XR (quetiapine fumarate) Extended Release Tablets as add-on treatment to antidepressants in adults with Major Depressive Disorder...
If you want to view the full text of this story, you must first purchase archive retrieval credits.